{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=17", "query": { "intervention": "capecitabine", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T03:53:02.151Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00889187", "title": "Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Neoadjuvant Short-Course Photon Radiation", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2009-12", "completion_date": "2011-12-30", "has_results": true, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889187" }, { "nct_id": "NCT01896869", "title": "FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Vaccine", "type": "BIOLOGICAL" }, { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2013-11", "completion_date": "2019-05-03", "has_results": true, "last_update_posted_date": "2020-05-19", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • St Louis, Missouri", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896869" }, { "nct_id": "NCT04034251", "title": "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer", "Esophagogastric Junction", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "BardPort Titanium Implanted Port with Peritoneal Catheter", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-06-09", "completion_date": "2024-09-05", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04034251" }, { "nct_id": "NCT05546411", "title": "A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Resectable Pancreatic Cancer", "Borderline Resectable Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "NIS793", "type": "DRUG" }, { "name": "Chemoradiation", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Kimberly Perez, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-01-06", "completion_date": "2023-10-13", "has_results": true, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05546411" }, { "nct_id": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Sonesitatug Vedotin", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "FLOT Chemotherapy", "type": "DRUG" }, { "name": "Calcium folinate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-07-17", "completion_date": "2029-07-16", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 7, "location_summary": "Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "North Shores", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07069712" }, { "nct_id": "NCT01234337", "title": "Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 537, "start_date": "2011-02-21", "completion_date": "2017-10-20", "has_results": true, "last_update_posted_date": "2018-11-06", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 19, "location_summary": "Greenbrae, California • Sylmar, California • West Palm Beach, Florida + 15 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234337" }, { "nct_id": "NCT03941366", "title": "Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Standard of care chemotherapy with the change for avoidance of extensive surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 15, "start_date": "2016-02-26", "completion_date": "2025-04-01", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03941366" }, { "nct_id": "NCT03487666", "title": "OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2018-05-21", "completion_date": "2024-05-02", "has_results": true, "last_update_posted_date": "2024-12-03", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03487666" }, { "nct_id": "NCT00068588", "title": "GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "GTI-2040", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2003-10", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068588" }, { "nct_id": "NCT04753879", "title": "Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-29", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-27T03:53:02.151Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753879" } ] }